Review Article
Pluripotent Stem Cells: Current Understanding and Future Directions
Table 1
Clinical trials using hESC- and hiPSC-derived products (modified by Trounson and McDonald [
107]).
| | Trial sponsor (location) | Targeted disease | Cell type | Phase | Clinical trial ID | Trial status | Reports |
| | Geron Corp. (USA) | Spinal cord injury | hES-derived OPCs | I | NCT01217008 | Complete | Not provided |
| | Asterias Biotherapeutics (USA) | Spinal cord injury | hES-derived OPCs | I/IIa | NCT02302157 | On-going | Not available yet |
| | Ocata Therapeutics (USA) | Stargardt’s macular dystrophy | hES-derived RPE | I/II | NCT01345006 | On-going |
[108, 109] | | Macular degeneration | hES-derived RPE | I/II | NCT01344993 | On-going | | Myopic macular degeneration | hES-derived RPE | I/II | NCT02122159 | Not open yet | — |
| | Pfizer (UK) | Macular degeneration | hES-derived RPE | I | NCT01691261 | On-going | Not available yet |
| | Cell Cure Neurosciences Ltd. (Israel) | Macular degeneration | hES-derived RPE | I/IIa | NCT02286089 | On-going | Not available yet |
| | Chabiotech Ltd. (South Korea) | Macular degeneration | hES-derived RPEs | I/IIa | NCT01674829 | On-going | [110] |
| | ViaCyte (USA) | Type-1 diabetes mellitus | hES-derived PP | I/II | NCT02239354 | On-going | Not available yet |
| Assistance Publique-Hôpitaux
de Paris (France) | Severe heart failure | hES-derived CD15 + Isl-1 + progenitors | I | NCT02057900 | On-going | Not available yet |
| | International Stem Cell Corp. (Australia) | Parkinson disease | hpESC-derived NSC | I | NCT02452723 | Not open yet | — |
| | RIKEN Center for Developmental Biology | Macular degeneration | iPSC-derived RPEs | I | — | On-going | Not available yet |
|
|
